June 22, 2017
Tata Consultancy Services recognised as a leader for life sciences drug safety services by IDC MarketScape
Report cites TCS’s strong technical focus, investments to drive innovation and ability to address strategic outsourcing needs
New York | Mumbai: Tata Consultancy Services (TCS), (BSE: 532540, NSE: TCS) a leading global IT services, consulting and business solutions organisation, has been recognised as a leader for life sciences drug safety services in the IDC MarketScape report titled, Worldwide Life Science Drug Safety Services Vendor Assessment 2017, (IDC #US42595616, June 2017), demonstrating the most mature strategies and capabilities among all vendors highlighted in the report.
The report noted TCS’s solid drug safety IT services and well-established business process services (BPS) drug safety capabilities, and highlighted TCS’s extensive experience working with life science companies, strong technical focus and investments to drive innovation in drug safety services.
IDC MarketScape assessed the capabilities and market successes of eight leading IT service providers that serve the life sciences sector in drug safety services. They were evaluated against breadth of service offerings, diversity of resources and infrastructure-supporting services delivery, project experience in the life sciences drug safety services market, customer service strategy and customer satisfaction, pricing model, go-to-market capabilities, and commitment to growth and innovation in the R&D drug safety space.
“TCS’s strong technical focus, willingness to invest to drive innovation in drug safety services, success with life science companies, including pharmaceuticals, biotech, medical devices, and animal health and broad service offerings make the company a strong partner for companies seeking a preferred vendor to address their operational and strategic outsourcing needs,” said the report's author, Alan S Louie, PhD, research director, clinical development strategy and technology, IDC Health Insights.
“Life sciences organisations are moving towards making personalised medicine a reality and demonstrating successful health outcomes,” said Debashis Ghosh, president, life sciences, manufacturing and energy business group, TCS. “This recognition by the IDC MarketScape reflects our commitment and ability to enable customers meet the requirements of ever-shifting drug safety regulatory landscape, and leverage digital technologies in modernising drug safety. Our market leading capabilities in both business process services and IT services makes us a partner of choice,” Mr Ghosh added.